Skip to main content
. 2022 Oct 12;12:1018034. doi: 10.3389/fonc.2022.1018034

Figure 2.

Figure 2

POLE EDMs induced cisplatin resistance in endometrial cancer cells. (A, B) HEK-293T cells were transfected with lentiviral vectors expressing negative control small hairpin RNA (shRNA NC) or shRNAs against POLE (shRNA1, shRNA2, shRNA3, or shRNA4). Quantitative real-time PCR (qRT-PCR) and Western blot analysis were performed at 48 h after transfection to determine mRNA and protein levels of POLE. (C, D) HEC-1A cells were transiently transfected with lentiviral vectors expressing wildtype POLE or P286R, R375Q, V411L, or P452L variant. Cells were treated with different concentrations of cisplatin (0.0001, 0.0128, 0.064, 0.32, 1.6, 8, 40, 100, 200, and 500 µmol/L) for 48–72 (h) MTT assay was conducted to measure the cell viability. IC50 was calculated. Data are expressed as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001, vs. WT; n = 3. WT, wildtype.